Option chain shows key data for Sernova Biotherapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Sernova Biotherapeutics.

Sernova Biotherapeutics (OTC:SEOVF) Stock, Option Chain

Sernova Biotherapeutics Inc is a clinical-stage company developing regenerative medicines. The company develops Cell Pouch with human donor cells or stem cells to create a biohybrid organ. The Cell Pouch is a implantable medical device designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells, which then release proteins, hormones, or other factors into the bloodstream for the long-term treatment of multiple chronic diseases such as type 1 diabetes, hypothyroid disease, and rare diseases such as hemophilia A.

News

Intraday Update

Markets

Movers

Trading Ideas

ABCAF

AGPPF

ANGPY

AOMOY

DMKBA

DOVA

IMPUY

LEN-B

MDNDF

NGCRF

OLCLF

PDYPY

PESI

PNNB

RLBY

SBGL

SEOVF

SMTGF

TGONF

AJINF

PDYPF

NPPNY

SBGLF

ELCTF

Stocks That Hit 52-Week Highs On Wednesday

ADES

ANSS

ARMK

ASMIY

ATEYY

AVGOP

BLDR

BONZ

BPYPP

BTDPF

CCRC

CELG

CELP

CHAG

CLHI

CLSI

CNSWF

CRVH

CRWS

CSVI

ECMH

ENGIY

EXLA

GLAD

GRBK

HCHMY

HELE

Hannover Ruckversicherungs Registered shares 

HVRRY

IBKCO

JACK

JRONF

LCSHF

LMRK

MANT

MTHRF

NCBDF

NXPI

OMRNY

ORKLF

ORKLY

PCTI

PFPT

ROST

SBAZ

SECCF

SEOJF

SFNXF

SKAS

SKSBF

SMTI

SPNS

SSREF

STIE

TERP

TMHC

TRCB

TREX

TSCHY

TTEK

TYOYY

USCR

UTRX

VOPKF

Stocks That Hit 52-Week Highs On Tuesday

SERNOVA BIOTHERAPEUTICS by SERNOVA BIOTHERAPEUTICS INC.

Sernova Biotherapeutics Inc

Press Releases

Sernova Biotherapeutics Receives FDA Clearance for IND Application for its Cell Pouch Bio-hybrid Organ with Autograft Thyroid Cells in Patients with Hypothyroidism

Financing

Sernova Biotherapeutics Secures $1 Million Convertible Debt Financing

Management

Sernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Development Officer and Head of R&D

Sernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch™ Bio-Hybrid Organ for Treatment of Type 1 Diabetes

Sernova Biotherapeutics Cell Pouch Bio-hybrid Organ to be Highlighted at Cell & Gene Meeting on the Med

Sernova Biotherapeutics Secures $4 Million Loan to Further Advance its Clinical Development Plans

Sernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 Diabetes

Sernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes

Comments

Sernova Biotherapeutics

Sernova Biotherapeutics (SEOVF) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell